New drug combo for recurrent ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called mocertatug rezetecan combined with bevacizumab against standard platinum chemo plus bevacizumab. It's for women with ovarian cancer that came back after treatment and is still sensitive to platinum drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your cancer must be a type called high-grade serous, high-grade endometrioid, clear cell, or carcinosarcoma.
- Your cancer must have come back after 1 or 2 previous treatments.
- Your cancer must be platinum-sensitive (came back more than 6 months after your last platinum chemo).
- You cannot have had certain previous treatments like a topoisomerase 1 inhibitor or a B7-H4 targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
This study tests a new maintenance therapy for people with advanced ovarian cancer that has responded well to initial chemotherapy. The goal is to see if it helps keep the cancer from coming back.
This trial tests a new drug, mocertatug rezetecan, combined with other anti-cancer therapies for people with advanced solid tumors like endometrial or ovarian cancer. It aims to see if the combination is safe and effective.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests a new drug (HS-20089) combined with another drug (bevacizumab) for women whose ovarian cancer has returned after responding to platinum-based chemotherapy. The goal is to see if this combination helps control the cancer better than standard options.
This study tests a combination of two drugs (trastuzumab rezetecan and bevacizumab) for women with ovarian cancer that has returned after initial treatment. The goal is to see if this combination helps control the cancer longer.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.